L-PRF in Cranial Surgery

NCT ID: NCT03812120

Last Updated: 2019-01-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators want to demonstrate in a prospective, randomized trial including 350 patients undergoing cranial surgery that the use of L-PRF is non-inferior to classical fibrin sealants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators want to demonstrate in a prospective, randomized trial including 350 patients undergoing cranial surgery that the use of L-PRF is non-inferior to classical fibrin sealants.

Approximately 350 patients undergoing cranial surgery will be enrolled in this randomized, controlled, single-blinded monocenter study to evaluate the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair (= primary objective).

The investigators will also evaluate if the use of L-PRF obviates the need for the use of other autologous grafts (e.g. muscle/fat), commercial collagen-based products (e.g. Tachosil) or articifial dura (=secondary objective).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cranial Sutures; Closure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized controlled clinical trial
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
Participants stay masked during the trial, care provider and investigators are unblinded at the surgical procedure and from thereon.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Classical Treatment

In this arm, dural closure will be performed with the classical fibrine sealants.

Group Type PLACEBO_COMPARATOR

Dural closure with classical fibrin sealants

Intervention Type PROCEDURE

Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair

L-PRF

In this arm, dural closure will be performed with the autologous L-PRF

Group Type ACTIVE_COMPARATOR

Dural closure with L-PRF

Intervention Type PROCEDURE

Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dural closure with L-PRF

Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair

Intervention Type PROCEDURE

Dural closure with classical fibrin sealants

Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing cranial neurosurgery whereby the dura is intentionally opened (supratentorial and infratentorial approach)
* Age ≥ 18 years
* Written informed consent
* Willing to comply with the study schedule

Exclusion Criteria

* Participation in another clinical trial with study drugs or devices
* Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tom Theys

Professor, Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tom Theys, Prof

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tom Theys

Leuven, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tom Theys, Prof

Role: CONTACT

003216344290 ext. 003216344290

Anais Van Hoylandt, Sc

Role: CONTACT

003216342012 ext. 003216342012

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tom Theys, Prof

Role: primary

003216344290 ext. 003216344290

Anais Van Hoylandt

Role: backup

003216342012 ext. 003216342012

References

Explore related publications, articles, or registry entries linked to this study.

Coucke B, De Vleeschouwer S, van Loon J, Van Calenbergh F, Van Hoylandt A, Van Gerven L, Theys T. Leukocyte- and platelet-rich fibrin in cranial surgery: a single-blinded, prospective, randomized controlled noninferiority trial. J Neurosurg. 2024 Feb 23;141(2):500-508. doi: 10.3171/2023.12.JNS232125. Print 2024 Aug 1.

Reference Type DERIVED
PMID: 38394657 (View on PubMed)

Coucke B, Van Hoylandt A, van Loon J, Van Calenbergh F, Van Gerven L, Theys T. Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial 1. Trials. 2023 Mar 23;24(1):219. doi: 10.1186/s13063-023-07252-w.

Reference Type DERIVED
PMID: 36959672 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

s61460

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Duraplasty for Acute Traumatic Spinal Cord Injury
NCT07280351 NOT_YET_RECRUITING NA